GlycoEra AG, a biotechnology company pioneering best-in-class extracellular protein degraders for the treatment of autoimmune diseases, closed an oversubscribed $130 million Series B financing. The ...

Hedera Dx, the European techbio company headquartered in Switzerland, just announced the closing of a €15 million Series A financing round to drive advanced cancer care. The funding will fuel Hedera ...